Total synthesis of fostriecin (CI-920) via a convergent route

Miyashita, Kazuyuki; Ikejiri, Masahiro; Kawasaki, Hitomi; Maemura, Satoko; Imanishi, Takeshi

doi:10.1039/b201302a

Cited by 44 publications

(19 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cloning of the PLM biosynthetic gene cluster and creation of a strain producing only PLM-B also set the stage for the generation of novel compounds with improved stability, activity, and selectivity. As such, this work represents a complementary approach to the widespread synthetic approaches directed toward this class of compounds (5,(17)(18)(19)(20)(21). One of the key structural differences between PLMs and fostriecin is the C-8 ethylamine substituent, which may contribute to less potent activity (15).…”

Section: Pcr-targeted Gene Disruption Of Plmsmentioning

confidence: 99%

“…Phase I clinical trials of fostriecin were suspended before either dose-limiting toxicities or therapeutic plasma levels were attained because of inherent drug instability and unpredictable purity in the clinical supply of the natural product (1,4). In an attempt to address these limitations and further develop this class of novel antitumor agents, no less than six elegant total syntheses of fostriecin have been developed over a short 2-year period (5,(17)(18)(19)(20)(21). A complementary approach for developing these agents can come through gene manipulation of the natural biosynthetic process.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Enhancement and Selective Production of Phoslactomycin B, a Protein Phosphatase IIa Inhibitor, through Identification and Engineering of the Corresponding Biosynthetic Gene Cluster

Palaniappan

Kim

Sekiyama

et al. 2003

Journal of Biological Chemistry

View full text Add to dashboard Cite

Section: Pcr-targeted Gene Disruption Of Plmsmentioning

confidence: 99%

mentioning

confidence: 99%

Enhancement and Selective Production of Phoslactomycin B, a Protein Phosphatase IIa Inhibitor, through Identification and Engineering of the Corresponding Biosynthetic Gene Cluster

Palaniappan

Kim

Sekiyama

et al. 2003

Journal of Biological Chemistry

View full text Add to dashboard Cite

“…Phase I clinical trials of fostriecin were reportedly halted due to inherent drug instability and unpredictable purity in the clinical supply of the natural products [22]. In an attempt to address these limitations and further develop this class of novel antitumor agents, no less than six total syntheses of fostriecin were developed over a short period of 2 years [1,6,7,26,33,50]. A total synthesis of LSN B has also been accomplished [39].…”

Section: Biological Activity Of the Plm And Related Compoundsmentioning

confidence: 98%

Genetic manipulation of the biosynthetic process leading to phoslactomycins, potent protein phosphatase 2A inhibitors

Ghatge

Palaniappan

Choudhuri

et al. 2006

J IND MICROBIOL BIOTECHNOL

View full text Add to dashboard Cite

Phoslactomycins (PLMs) represent an unusual structural class of natural products secreted by various streptomycetes, containing an alpha,beta-unsaturated delta-lactone, an amino group, phosphate ester, conjugated diene and a cyclohexane ring. Phosphazomycins, phospholines and leustroducsins contain the same structural moieties, varying only in the acyl substituent at the C-18 hydroxyl position. These compounds possess either antifungal or antitumor activities or both. The antitumor activity of the PLM class of compounds has been attributed to a potent and selective inhibition of protein phosphatase 2A (PP2A). The cysteine-269 residue of PP2Ac-subunit has been shown to be the site of covalent modification by PLMs. In this article, we review previous work on the isolation, structure elucidation and biological activities of PLMs and related compounds and current status of our work on both PLM stability and genetic manipulation of the biosynthetic process. Our work has shown that PLM B is surprisingly stable in solution, with a pH optimum of 6. Preliminary biosynthetic studies utilizing isotopically labeled shikimic acid and cyclohexanecarboxylic acid (CHC) suggested PLM B to be a polyketide-type antibiotic synthesized using CHC as a starter unit. Using a gene (chcA) from a set of CHC-CoA biosynthesis genes from Streptomyces collinus as a probe, a 75 kb region of 29 ORFs encoding PLM biosynthesis was located in the genome of Streptomyces sp. strain HK803. Analysis and subsequent manipulation of plmS2 and plmR2 in the gene cluster has allowed for rational engineering of a strain that produces only one PLM analog, PLM B, at ninefold higher titers than the wild type strain. A strain producing PLM G (the penultimate intermediate in PLMs biosynthesis) has also been generated. Current work is aimed at selective in vitro acylation of PLM G with various carboxylic acids and a precursor-directed biosynthesis in a chcA deletion mutant with the aim of generating novel PLM analogs.

show abstract

“…40,99,100 The C11 stereocenter is derived from the chiral pool, while the C8 and C9 stereocenters arise from a Sharpless asymmetric dihydroxylation. 66,67 A Stille 73 cross-coupling connects the triene to the core of the molecule.…”

Section: Fostriecinmentioning

confidence: 99%

Synthetic Strategies Employed for the Construction of Fostriecin and Related Natural Products

2016

View full text Add to dashboard Cite

Fostriecin and related natural products present a significant challenge for synthetic chemists due to their structural complexity and chemical sensitivity. This review will chronicle the successful efforts of synthetic chemists in the construction of these biologically active molecules. Key carbon–carbon bond forming reactions will be highlighted, as well as the methods used to install the numerous stereocenters present in this class of compounds.

show abstract

Total synthesis of fostriecin (CI-920) via a convergent route

Abstract: Fostriecin, a potent and promising antitumor antibiotic, was stereoselectively synthesized via a convergent route involving a three-segement coupling procedure.

Cited by 44 publications

References 17 publications

Enhancement and Selective Production of Phoslactomycin B, a Protein Phosphatase IIa Inhibitor, through Identification and Engineering of the Corresponding Biosynthetic Gene Cluster

Enhancement and Selective Production of Phoslactomycin B, a Protein Phosphatase IIa Inhibitor, through Identification and Engineering of the Corresponding Biosynthetic Gene Cluster

Genetic manipulation of the biosynthetic process leading to phoslactomycins, potent protein phosphatase 2A inhibitors

Synthetic Strategies Employed for the Construction of Fostriecin and Related Natural Products

Contact Info

Product

Resources

About